Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
Retrospective case-control study shows 92% vaccine effectiveness against RSV-related emergency department visits in older adults, indicating protection for high-risk populations.
Key Points
92% vaccine effectiveness against RSV-related hospitalization or emergency department visits, supporting substantial efficacy in older adults.
Among 8965 ARI visits, only 7.8% tested positive for RSV, with just 0.3% having received the RSVpreF vaccine.
The analysis was a retrospective case-control study of adults aged ≥60 years, utilizing multivariable logistic regression for vaccine effectiveness calculation.
This emphasizes the potential for RSV vaccination programs to significantly reduce severe disease outcomes in high-risk subgroups.